World's Best Scientists 2026 revealed!
Pierre-Yves Dietrich

Pierre-Yves Dietrich

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Immunology 72 2199 2020 57 48 285 21155
Medicine 73 19614 18407 299 286 310 21674

Pierre-Yves Dietrich publications per year

The chart shows the history of publications by Pierre-Yves Dietrich between 1986 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Pierre-Yves Dietrich published across 40 years, from 1986 to 2025, averaging 8.8 papers a year. Output peaked at 27 publications in 2018. 10 of the 352 publications appeared in the last two years.

No. of publications
5 10 15 20 25
Bar chart. Horizontal axis: year, 1986 to 2025. Vertical axis: number of publications, 0 to 27. Peak 27 publications in 2018. 1986: 1 publication 1987: 0 publications 1988: 0 publications 1989: 3 publications 1990: 0 publications 1991: 2 publications 1992: 1 publication 1993: 6 publications 1994: 3 publications 1995: 6 publications 1996: 4 publications 1997: 9 publications 1998: 6 publications 1999: 5 publications 2000: 8 publications 2001: 8 publications 2002: 16 publications 2003: 10 publications 2004: 8 publications 2005: 8 publications 2006: 3 publications 2007: 9 publications 2008: 10 publications 2009: 11 publications 2010: 6 publications 2011: 8 publications 2012: 12 publications 2013: 18 publications 2014: 9 publications 2015: 15 publications 2016: 14 publications 2017: 14 publications 2018: 27 publications 2019: 14 publications 2020: 16 publications 2021: 14 publications 2022: 11 publications 2023: 27 publications 2024: 7 publications 2025: 3 publications
1986 2025

352 publications in total across all disciplines

View publications per year as a table
Pierre-Yves Dietrich: publications per year, 1986 to 2025
Year Publications
1986 1
1987 0
1988 0
1989 3
1990 0
1991 2
1992 1
1993 6
1994 3
1995 6
1996 4
1997 9
1998 6
1999 5
2000 8
2001 8
2002 16
2003 10
2004 8
2005 8
2006 3
2007 9
2008 10
2009 11
2010 6
2011 8
2012 12
2013 18
2014 9
2015 15
2016 14
2017 14
2018 27
2019 14
2020 16
2021 14
2022 11
2023 27
2024 7
2025 3
Total 352
Download as CSV

Pierre-Yves Dietrich publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Pierre-Yves Dietrich sits on this spectrum.

No. of scientists
50 100 150
Bar chart with 76 bars. Horizontal axis: publications, 62–71 to 807+. Vertical axis: number of scientists, 0 to 189. Most scientists, 189, have 152–161 publications. The last bar groups every scientist with 807 publications or more. The highlighted bar, 282–291 publications, is where this scientist sits. 62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientist 807+ publications: 100 scientists
62–71 publications 807+

This scientist: 285 publications — 61st percentile

61% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

View publications distribution as a table
Number of Immunology scientists by publication count, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
Publications Scientists This scientist
62–71 9
72–81 23
82–91 40
92–101 72
102–111 86
112–121 108
122–131 150
132–141 160
142–151 159
152–161 189
162–171 166
172–181 181
182–191 188
192–201 187
202–211 178
212–221 158
222–231 168
232–241 159
242–251 160
252–261 148
262–271 116
272–281 125
282–291 115 285
292–301 111
302–311 95
312–321 97
322–331 97
332–341 99
342–351 96
352–361 69
362–371 76
372–381 71
382–391 71
392–401 62
402–411 54
412–421 41
422–431 63
432–441 53
442–451 31
452–461 42
462–471 40
472–481 29
482–491 34
492–501 30
502–511 23
512–521 41
522–531 29
532–541 28
542–551 16
552–561 18
562–571 18
572–581 17
582–591 17
592–601 17
602–611 19
612–621 13
622–631 12
632–641 11
642–651 16
652–661 9
662–671 5
672–681 13
682–691 12
692–701 6
702–711 6
712–721 9
722–731 9
732–741 6
742–751 11
752–761 10
762–771 7
772–781 12
782–791 7
792–801 5
802–806 1
807+ 100
Download as CSV

Pierre-Yves Dietrich D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Pierre-Yves Dietrich sits on this spectrum.

No. of scientists
50 100 150 200
Bar chart with 60 bars. Horizontal axis: D-Index, 40–41 to 157+. Vertical axis: number of scientists, 0 to 201. Most scientists, 201, have 58–59 D-Index. The last bar groups every scientist with 157 D-Index or more. The highlighted bar, 72–73 D-Index, is where this scientist sits. 40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40–41 D-Index 157+

This scientist: 72 D-Index — 56th percentile

56% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

View D-Index distribution as a table
Number of Immunology scientists by D-index, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
D-Index Scientists This scientist
40–41 28
42–43 91
44–45 157
46–47 192
48–49 175
50–51 188
52–53 177
54–55 155
56–57 194
58–59 201
60–61 197
62–63 201
64–65 173
66–67 167
68–69 172
70–71 199
72–73 184 72
74–75 133
76–77 163
78–79 127
80–81 121
82–83 125
84–85 121
86–87 102
88–89 96
90–91 75
92–93 72
94–95 74
96–97 66
98–99 68
100–101 49
102–103 60
104–105 54
106–107 36
108–109 23
110–111 52
112–113 41
114–115 34
116–117 25
118–119 28
120–121 11
122–123 20
124–125 27
126–127 19
128–129 20
130–131 16
132–133 17
134–135 14
136–137 15
138–139 9
140–141 11
142–143 9
144–145 9
146–147 7
148–149 7
150–151 7
152–153 5
154–155 8
156 6
157+ 96
Download as CSV

Overview

Pierre-Yves Dietrich is affiliated with the University of Geneva in Switzerland and has contributed extensively to the field of medicine, with a primary focus on oncology. Their body of work spans multiple subfields including oncology, immunology, molecular biology, genetics, and infectious diseases.

Their research intersects a variety of topics such as:

  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • Glioma Diagnosis and Treatment
  • Cancer survivorship and care
  • CAR-T cell therapy research
  • Colorectal and Anal Carcinomas
  • SARS-CoV-2 and COVID-19 Research

Dietrich's recent publications include:

  • "The probabilistic model of Alzheimer disease: the amyloid hypothesis revised," 2021, Nature reviews. Neuroscience
  • "Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy," 2021, Science Immunology
  • "Inflammation and lymphocyte infiltration are associated with shorter survival in patients with high-grade glioma," 2020, OncoImmunology
  • "Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis," 2023, Nature Medicine
  • "Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?", 2021, Cancer Treatment Reviews

Frequent coauthors with whom Dietrich has collaborated include:

  • Valérie Dutoit
  • Solange Peters
  • Thomas McKee
  • Eliana Marinari
  • Petros Tsantoulis

Their work has been published repeatedly in venues such as:

  • Revue Médicale Suisse
  • Nature Medicine
  • Cancers
  • Journal of Clinical Oncology
  • BMC Cancer

Dietrich's extensive publication record in medicine includes 91 works, with a significant number addressing oncology through 40 publications and immunology through 13 publications. Their research contributions contribute to a broad understanding of cancer biology, immune mechanisms in cancer therapy, molecular and genetic pathways involved in disease, and infectious disease intersections.

Best Publications

  • Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

    Steffen Walter;Toni Weinschenk;Arnulf Stenzl;Romuald Zdrojowy

  • Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

    M Marchand;N van Baren;N van Baren;P Weynants;P Weynants;V Brichard;V Brichard;V Brichard

  • Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide

    Roger Stupp;Pierre Yves Dietrich;Sandrine Ostermann Kraljevic;Alessia Pica

  • Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide

    Monika E. Hegi;Annie Claire Diserens;Sophie Godard;Pierre Yves Dietrich

  • Actively personalized vaccination trial for newly diagnosed glioblastoma

    Norbert Hilf;Sabrina Kuttruff-Coqui;Katrin Frenzel;Valesca Bukur

  • Stem Cell–Related “Self-Renewal” Signature and High Epidermal Growth Factor Receptor Expression Associated With Resistance to Concomitant Chemoradiotherapy in Glioblastoma

    Anastasia Murat;Eugenia Migliavacca;Thierry Gorlia;Wanyu L Lambiv

  • Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

    Roger Stupp;Monika E. Hegi;Bart Neyns;Roland Goldbrunner

  • Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?

    P Saas;P R Walker;M Hahne;A L Quiquerez

  • Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type

    Annarita Conconi;Giovanni Martinelli;Catherine Thiéblemont;Andrés J M Ferreri

  • Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

    M. Brada;K. Hoang-Xuan;R. Rampling;P. Y. Dietrich

  • The probabilistic model of Alzheimer disease: the amyloid hypothesis revised.

    Giovanni B Frisoni;Giovanni B Frisoni;Daniele Altomare;Daniele Altomare;Dietmar Rudolf Thal;Federica Ribaldi

  • An experimentally validated panel of subfamily‐specific oligonucleotide primers (Vα1‐w29/Vβ1‐w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction

    Catherine Genevée;Anita Diu;Janine Nierat;Anne Caignard

  • MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status

    Pierre Bady;Davide Sciuscio;Annie Claire Diserens;Jocelyne Bloch

  • Classification of Human Astrocytic Gliomas on the Basis of Gene Expression A Correlated Group of Genes with Angiogenic Activity Emerges As a Strong Predictor of Subtypes

    Sophie Godard;Gad Getz;Mauro Delorenzi;Pierre Farmer

  • Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98

    Giovanni Martinelli;Shu Fang Hsu Schmitz;Urs Utiger;Thomas Cerny

  • Homing Phenotypes of Tumor-Specific CD8 T Cells Are Predetermined at the Tumor Site by Crosspresenting APCs

    Thomas Calzascia;Frédérick Masson;Wilma Di Berardino-Besson;Emmanuel Contassot

  • Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy

    Valérie Dutoit;Christel Herold-Mende;Norbert Hilf;Oliver Schoor

  • Tumoral and Immunologic Response After Vaccination of Melanoma Patients With an ALVAC Virus Encoding MAGE Antigens Recognized by T Cells

    Nicolas van Baren;Marie-Claude Bonnet;Brigitte Dréno;Amir Khammari

  • Complete Remission With Tyrosine Kinase Inhibitors in Renal Cell Carcinoma

    Laurence Albiges;Stéphane Oudard;Sylvie Negrier;Armelle Caty

  • Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer.

    Alfredo Addeo;Pankil K. Shah;Natacha Bordry;Robert D. Hudson

  • Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.

    Pedro Romero;Danila Valmori;Mikael J. Pittet;Alfred Zippelius

Frequent Co-Authors

Hans-Georg Rammensee
Hans-Georg Rammensee University of Tübingen
Stefan Stevanovic
Stefan Stevanovic University of Tübingen
Jean-Charles Cerottini
Jean-Charles Cerottini University of Lausanne
Daniel E. Speiser
Daniel E. Speiser University of Lausanne
Wolfgang Wick
Wolfgang Wick German Cancer Research Center
Pedro Romero
Pedro Romero University of Lausanne
Solange Peters
Solange Peters University Hospital of Lausanne
Andreas von Deimling
Andreas von Deimling Heidelberg University
Danila Valmori
Danila Valmori University of Nantes
Mikael J. Pittet
Mikael J. Pittet University of Geneva

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in pursuing Immunology, exploring related online degrees can open diverse career opportunities in healthcare. Many students consider specialized nursing paths such as Psychiatric-Mental Health Nurse Practitioner (PMHNP) programs, which often include hands-on experience through online pmhnp programs with clinical placement. These programs ensure graduates gain essential practical skills alongside theoretical knowledge.

Cost is a major factor when selecting a program. Prospective students may want to research the cheapest pmhnp certificate programs, which provide quality education without excessive financial burden. This accessibility helps more individuals enter the field and contribute to Immunology-related healthcare services.

Understanding potential earnings is crucial for career planning. For example, a Doctor of Nursing Practice (DNP) degree often leads to higher salaries. You can learn more about compensation by reviewing data on how much does a dnp make, helping you assess the long-term value of advanced degrees relevant to Immunology.

Additionally, for nurses already certified as Family Nurse Practitioners (FNPs), there are bridge options to specialize further. Programs like the fnp to acute care np bridge program allow smooth transitions into more acute roles, which can align with Immunology’s clinical demands.

Best Scientists Citing Pierre-Yves Dietrich

Trending Scientists

Recently Published Articles